Furkan Ozmen

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway

The paper identifies resistance mechanisms to KRAS-MEK pathway targeting in PDAC by analyzing clinical trial data and multi-omics profiles, showing that KRAS/MYC co-gain correlates with resistance and that co-targeting these genes is synergistic.

Neoplastic immune mimicry potentiates breast tumor progression

This study identifies immune mimicry in breast cancer cells, where neoplastic cells express leukocyte receptors, enhancing tumor aggressiveness and therapy resistance.

Tumor-intrinsic MHC-II activation in pancreatic ductal adenocarcinoma enhances immune response and treatment efficacy

This study shows that MHC-II expression in pancreatic cancer cells correlates with immune infiltration and improves immunotherapy response in mouse models.

Automated Machine Learning Profiling with MAP-HR for Quantifying Homologous Recombination Foci in Patient Samples

The paper introduces MAP-HR, a machine learning platform for quantifying homologous recombination foci in patient samples to assess HR deficiency and guide therapy.

Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

This study identifies a p53 mutation-specific immunotherapy strategy for ovarian cancer by targeting AREG and PD-L1, showing efficacy in mouse models and patient-derived organoids.